Clinical Trials Logo

Chemotherapy Induced Anemia clinical trials

View clinical trials related to Chemotherapy Induced Anemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06075030 Not yet recruiting - Clinical trials for Chemotherapy Induced Anemia

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Start date: December 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

NCT ID: NCT05301517 Completed - Clinical trials for Chemotherapy Induced Anemia

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Start date: March 16, 2022
Phase: Phase 3
Study type: Interventional

The main goal of this study is to evaluate the efficacy of roxadustat for treatment of anemia in participants with non-myeloid malignancies receiving multi-cycle treatments of myelosuppressive chemotherapy.

NCT ID: NCT04076943 Completed - Clinical trials for Chemotherapy Induced Anemia

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Start date: August 20, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.

NCT ID: NCT02158169 Completed - Clinical trials for Chemotherapy-induced Anemia

Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology

SYNERGY
Start date: June 2012
Phase: N/A
Study type: Observational

The aim of this study is to describe, in a real-life context, the impact of an epoetin alpha biosimilar, Retacrit®, on anaemia in patients receiving chemotherapy, according to concomitant iron supplementation.

NCT ID: NCT00931606 Terminated - Clinical trials for Chemotherapy Induced Anemia

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

Start date: June 1, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).

NCT ID: NCT00272662 Completed - Cancer Clinical Trials

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.

NCT ID: NCT00144495 Completed - Clinical trials for Chemotherapy Induced Anemia

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Start date: February 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

NCT ID: NCT00144482 Completed - Clinical trials for Chemotherapy Induced Anemia

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Start date: December 2003
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy